Both Hershey and Vertex Pharmaceuticals show bearish death cross technical signals, yet analysts remain bullish with significant upside targets. Hershey's fundamentals are strong with earnings beats and steady revenue growth, while Vertex benefits from robust earnings momentum and promising drug pipeline catalysts. Institutional investors hold large stakes, indicating confidence despite technical warnings. The consensus suggests these bearish signals are late and weak, with potential for price recovery ahead, though risks remain if negative news emerges.
The SCHD ETF has returned just under 2% in the past month, outperforming the S&P 500 ETF (SPY) by nearly 1%. Year-to-date, about 30 SCHD holdings have more than doubled the returns of SPY, which has returned 9.8%. Additionally, 31 SCHD holdings are t...
Hershey is now considered an attractive investment after a period of underperformance, offering a 3.3% dividend yield. The company is experiencing net sales growth and improving gross margins, driven by pricing strategies and supply chain efficiencie...
